Opendata, web and dolomites

MYCure SIGNED

Innovative cancer therapy through Myc inhibition: taking OMO-103 to market

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MYCure project word cloud

Explore the words cloud of the MYCure project. It provides you a very rough idea of what is the project "MYCure" about.

rounds    2029    small    market    15    clinical    company    instrument    combines    cells    revolutionizing    companies    closed    projected    annually    considerable    myc    sound    omo    scientific    gain    too    leadership    acumen    poised    deaths    capitals    addressable    business    evolve    contrast    sme    pharmaceutical    excellence    cell    venture    share    world    accounting    ground    patented    treatments    foundation    2023    completing    global    proteins    surface    men    inhibitor    trials    despite    2018    pressing    ineffective    redundant    investments    biotech    survival    licensing    20    total    plan    record    treat    innovative    toxic    financing    clear    safer    kill    nuclei    millions    mycure    class    compensated    70    women    equity    peptomyc    receptors    inhibiting    treatment    tumours    thanks    therapies    lung    cancer    14    commercialization    efficient    attack    models    bn    inhibition    103    first    builds    full    toxicity    breaking    penetrate    resistance   

Project "MYCure" data sheet

The following table provides information about the project.

Coordinator
PEPTOMYC SL 

Organization address
address: CENTER CELLEX, CALLE NATZARET 115-117
city: BARCELONA
postcode: 8035
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙170˙790 €
 EC max contribution 2˙219˙553 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PEPTOMYC SL ES (BARCELONA) coordinator 2˙219˙553.00

Map

 Project objective

Cancer is a global challenge with 9 millions (M) deaths annually and new cases projected to rise by 70% in the 20 years, and there is a clear and pressing need for more effective therapies. In the EU, lung cancer is the most common cancer in men and the third most common in women, with 2 M new cases in 2018 accounting for ~20% of all cancer deaths. Despite considerable recent advances in lung cancer treatment, current treatments are still too often ineffective or highly toxic. Peptomyc is a unique biotech SME that is revolutionizing cancer treatment with its ground-breaking innovative cancer therapies inhibiting Myc. Our patented product OMO-103 is able to penetrate the nuclei, attack Myc and kill cancer cells. In contrast, most current therapies attack redundant cell surface receptors or proteins that can be compensated by tumours, which then evolve resistance. Our company combines scientific excellence with sound business acumen: our scientific leadership in Myc inhibition builds on 20 years of world-class scientific record, and in just 3 years after the foundation, we closed 2 rounds of equity investments with Venture Capitals. Peptomyc aims at licensing its technology to pharmaceutical companies. Financing through this SME Instrument project will enable us to take to the market our first product, OMO-103 by completing clinical trials and reach a licensing agreement with a pharmaceutical company for full scale production and commercialization. Our results so far show that OMO-103 is: Safer (no toxicity), More efficient (no resistance observed), and More effective (increased survival in lung cancer models). With MYCure, we will take to market our first-in-class Myc inhibitor OMO-103 to treat non-small cell lung cancer, for which the global market is expected to reach 14 bn € by 2023, a total addressable market of which OMO-103 is poised to gain considerable share of up to 15% by 2029 thanks to a sound business plan developed under the SME Instrument.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYCURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYCURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More